Cycling alpha cells in regenerative drug-treated human pancreatic islets may serve as key beta cell progenitors

Diabetes results from an inadequate number of insulin-producing human beta cells. There is currently no clinically available effective means to restore beta cell mass in millions of people with diabetes. Although the DYRK1A inhibitors, either alone or in combination with GLP-1 receptor agonists (GLP-1) or transforming growth factor β (TGF-β) superfamily inhibitors (LY), induce beta cell replication and increase beta cell mass, the precise mechanisms of action remain elusive. Here we perform single-cell RNA sequencing on human pancreatic islets treated with a DYRK1A inhibitor, either alone or with GLP-1 or LY. We identify cycling alpha cells as the most responsive cells to DYRK1A inhibition. Lineage trajectory analyses suggest that cycling alpha cells may serve as precursor cells that transdifferentiate into beta cells. Collectively, in addition to enhancing expression of beta cell phenotypic genes in beta cells, our findings suggest that regenerative drugs may be targeting cycling alpha cells in human islets.

Authors

Institutions

Publication Details

Journal
Cell Reports Medicine
Published
2024-12-01
DOI
https://doi.org/10.1016/j.xcrm.2024.101832
Citations
12
Primary Topic
Pancreatic function and diabetes
Type
article
Field-Weighted Citation Impact
6.87

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cycling alpha cells in regenerative drug-treated human pancreatic islets may serve as key beta cell progenitors

Adolfo Garcı́a-Ocaña, Deniz Demircioğlu, Randy B. Kang, Esra Karaköse et al.
12 citations
Cell Reports Medicine
Pancreatic function and diabetes
6.87
article

Cycling alpha cells in regenerative drug-treated human pancreatic islets may serve as key beta cell progenitors

Adolfo Garcı́a-Ocaña, Deniz Demircioğlu, Randy B. Kang, Esra Karaköse, Geming Lu, Andrew F. Stewart, Xuedi Wang, Carmen Argmann, Saul Carcamo, Donald K. Scott, Robert Sebra, Luca Lambertini, Peng Wang, Dan Hasson, Olivia Wood
article en
12 citations

Abstract

Diabetes results from an inadequate number of insulin-producing human beta cells. There is currently no clinically available effective means to restore beta cell mass in millions of people with diabetes. Although the DYRK1A inhibitors, either alone or in combination with GLP-1 receptor agonists (GLP-1) or transforming growth factor β (TGF-β) superfamily inhibitors (LY), induce beta cell replication and increase beta cell mass, the precise mechanisms of action remain elusive. Here we perform single-cell RNA sequencing on human pancreatic islets treated with a DYRK1A inhibitor, either alone or with GLP-1 or LY. We identify cycling alpha cells as the most responsive cells to DYRK1A inhibition. Lineage trajectory analyses suggest that cycling alpha cells may serve as precursor cells that transdifferentiate into beta cells. Collectively, in addition to enhancing expression of beta cell phenotypic genes in beta cells, our findings suggest that regenerative drugs may be targeting cycling alpha cells in human islets.

Cell Reports MedicineVol. 5(12)
Icahn School of Medicine at Mount Sinai (US)
Icahn School of Medicine at Mount Sinai, Georgia Clinical and Translational Science Alliance, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences
Zero hunger, Good health and well-being
Openalex Percentile: Top 2%
Pancreatic function and diabetes
6.87
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.